Refreshing model for Roche collab and 2Q results

Research evidence excerpt

Refreshing model for Roche collab and 2Q results

Update

July 27, 2026 08:30 PM GMT

Morgan Stanley & Co. LLCMNurix Therapeutics Inc. | North America Terence C Flynn, Ph.D.

Equity Analyst

Refreshing model for Roche Terence.Flynn@morganstanley.comAlexander Yevdokimov, Ph.D. +1 212 761-2230

Research Associate

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

collab and 2Q results Hailey Horowitz

What’s Changed Hailey.Horowitz@morganstanley.com +1 212 761-5264

Chris Yu, J.D., Ph.D.

Nurix Therapeutics Inc. (NRIX.O) From To Equity Analyst

Price Target $36.00 $38.00 Chris.L.Yu@morganstanley.com +1 212 761-2535

Damien H Kerner

We update our model for recently closed Roche collaboration ResearchDamien.H.Kerner@morganstanley.comAssociate +1 212 761-3829

and our PT goes to $38. The Bexdeg Ph2 DAYBreak CLL trial Connor M Massari

continues to enroll patient, and the Ph3 DAYBreak CLL-306 EquityConnor.Massari@morganstanley.comAnalyst +1 212 761-2417

study in 2L+ is expected to begin mid-year. We also update our Morgan Stanley India Company Private Limited+

model for 2Q results. Saket Agarwal

Saket.Agarwal@morganstanley.com +91 22 6995-4012

NRIX recently reported 2Q26 results, with timelines generally reiterated.

Enrollment for the Ph1a NX-1607 study (CBL-B inhibitor for oncology Nurix Therapeutics Inc. (NRIX.O, NRIX US)

indications) and the Ph1 dose-escalation cohort of Zelebrudomide (BTK degrader Biotechnology | United States of America

for B-cell malignancies) is complete, and the company is reviewing the data to Stock Rating Overweight

determine next steps (LINK). Industry View Attractive

Price target $38.00

Shr price, close (Jul 24, 2026) $23.38

Key Takeaways: (1) Bexobrutideg (bexdeg; oral BTK degrader without IMiD Mkt cap, curr (mm) $2,604